STUDresearch · Peptide
Sotatercept
Also known as
Winrevair · ACE-011 (related) · sotatercept-csrk
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
SubQ
Growth factors / muscle
Systemic ActRIIA fusion biologic for PAH.
What people say
Sotatercept-csrk is an ActRIIA-Fc fusion biologic approved as WINREVAIR for adults with pulmonary arterial hypertension. It is ongoing specialist treatment added to background PAH therapy, not a gray-market muscle or recovery peptide.
Doses people talk about
These are prescribing-label exposures for adults with PAH, not self-directed dose bands. Hemoglobin and platelet results can delay or change treatment.
How it may feel
Patient timing varied from same-day improvement to change after the second through fourth doses, several months, persistent fatigue or no subjective change. Headache, diarrhea, fatigue and nosebleeds were also reported; background therapy and comorbidities complicate attribution.
Labeled starting exposure0.3 mg/kg SC once
The label calls for hemoglobin and platelet testing before treatment; escalation occurs only after acceptable values.
Labeled target exposure0.7 mg/kg SC every three weeks
Ongoing treatment follows the labeled schedule unless hemoglobin or platelet changes require delay or adjustment.
Half-life & effect duration
- Half-life in the body
- Under-the-skin injection · PAH studyAbout 24 days
- Felt duration people report
- Breathing / energy reportsFirst day, after 2–4 doses, or several months
- Other accountsPersistent fatigue or no subjective change after multiple doses
Cycles people discuss
The approved schedule is continuing treatment every three weeks, with hemoglobin and platelet monitoring and label-defined delays or re-escalation. Fixed self-directed on/off cycles do not describe this therapy.
Timing
Treatment visits are coordinated with hemoglobin and platelet checks. The labeled three-week schedule can be delayed or adjusted for those results, and escalation after the initial dose depends on acceptable counts. Timing is specialist-directed, not a self-managed cycle.
Stacks
Sotatercept is used as an add-on to established PAH therapy, not a solo research run. Prostacyclin or antithrombotic background treatment may also affect bleeding risk, so combination decisions belong to the PAH specialist.
Watch for
Major labeled risks: WINREVAIR can cause erythrocytosis with thromboembolic or hyperviscosity risk, severe thrombocytopenia and serious bleeding; the label also warns of embryo-fetal toxicity and impaired fertility. Hemoglobin and platelet monitoring and specialist-directed dose holds or changes are part of treatment.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Sotatercept-csrk has an effective half-life of approximately 24 days in PAH patients.
The 2026 FDA label reports this after subcutaneous treatment, with median time to peak around seven days and steady state around 15 weeks.
Effective half-life is a population PK parameter; it does not predict an individual's day of symptom improvement or authorize schedule changes.
- FDA — WINREVAIR (sotatercept-csrk) prescribing information, revised March 2026 (opens in a new tab)Current label gives the adult PAH indication, 0.3 mg/kg starting dose, 0.7 mg/kg every-three-week target, monitoring rules, adverse reactions, seven-day median Tmax, 15-week steady state and 24-day effective half-life.Prescribing information summarizes regulated clinical evidence; it is not individualized medical advice and subjective improvement timing varies.
Felt duration people report
Patients report very different times to perceived breathing or energy change.
In two inspected discussions, reports ranged from the first day or first dose to the second through fourth dose, several months, persistent fatigue or no subjective change after multiple doses.
Anonymous accounts reflect differing PAH severity, background drugs, comorbidities and outcomes; they do not measure drug PK or prove causality.
- Reddit r/PulmonaryHypertension — What has been your experience with Winrevair? (opens in a new tab)Multiple patients report timing from first day to second through fourth dose or months, persistent fatigue, headache, diarrhea and later nosebleeds; the initiating author reports no change after the first dose.Anonymous multi-author patient discussion with different disease severity, background therapies, comorbidities and follow-up; cannot estimate prevalence or causal timing.
- Reddit r/PulmonaryHypertension — Winrevair energy-level experiences (opens in a new tab)Same initiating author updates from one to three doses without energy improvement while other users report change after two doses, months, better breathing with weakness or no difference.Anonymous discussion; same-author updates preserve chronology but do not control background treatment, iron status, disease progression or reporting bias.
What people say
- PAH outcomes: Clinical program improved outcomes in pulmonary arterial hypertension. trial
- Approved PAH use: WINREVAIR is an activin-signaling inhibitor added to background therapy for adults with pulmonary arterial hypertension to improve exercise capacity and functional class and reduce clinical-worsening events. This is not evidence for bodybuilding recomposition or soft-tissue recovery. trial
- Background-therapy context: Clinical trials and patient reports generally involve sotatercept added to established PAH treatment, so changes cannot be interpreted as unmonitored solo-drug or training outcomes. trial
- Monitoring is treatment-critical: Hemoglobin and platelets are checked before each of the first five doses and periodically thereafter because erythrocytosis, thrombocytopenia and bleeding can require delay or dose modification. This is not PCT or lipid-cycle monitoring. trial
- Ongoing specialist treatment: The label describes subcutaneous dosing every three weeks with laboratory-guided delays or re-escalation, not fixed bodybuilding on/off cycles. trial
Doses people talk about
- Not a daily gray-market muscle peptide. forum
- Labeled starting dose: 0.3 mg/kg by subcutaneous injection once, followed three weeks later by escalation only after acceptable hemoglobin and platelet counts. trial
- Labeled target dose: 0.7 mg/kg by subcutaneous injection every three weeks unless label-defined laboratory changes require delay or adjustment. trial
- Framing: Prescription ActRIIA-Fc for PAH — specialist only. trial
How it may feel
- After an early dose: Sotatercept is subcutaneous, not oral. In patient discussion, some reported no benefit after one dose, while others described improvement from the first day; headache, diarrhea or vaccine-like fatigue were also reported. forum
- Day one is variable: One patient reported immediate improvement in breathing and household activity, while the thread's author noticed no fatigue or breathing improvement one week after the first dose. forum
- First weeks: Reports range from immediate change to no change after one or several doses. Concurrent PAH drugs and comorbidities remain major attribution limits. forum
- Later response reports: Several patients described improvement around the second to fourth three-week dose, while others reported months, persistent fatigue or no subjective change. Nosebleeds and delayed doses also appear in longer follow-up. forum
- Chronic specialty care: Months under clinicians. trial
Cycles people discuss
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Ongoing prescription treatment: Sotatercept is administered subcutaneously every three weeks under specialist guidance, with hemoglobin and platelet monitoring and label-defined delays when needed. trial
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
- Not a self-directed cycle: The label uses continuing three-week intervals and laboratory-guided delay rules; a weeks-on/weeks-off bodybuilding pattern does not describe sotatercept treatment. trial
Timing
- Felt timing differs from PK: Patient reports ranged from same-day improvement to change after two to four doses, several months, or no subjective benefit; this does not alter the measured 24-day effective half-life. forum
- Measured human PK: After subcutaneous treatment in PAH studies, sotatercept-csrk had an effective half-life of about 24 days; median time to peak concentration was about seven days and steady state was reached after about 15 weeks. trial
- Published PK: Where human PK exists it should override forum half-life memes for Sotatercept. trial
More on what it is
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for Sotatercept, not proof it works for you. forum
- What it is: Activin signaling inhibitor (ActRIIA-Fc) approved/developed in PAH (Winrevair) — serious prescription biologic. trial
- Not a research-chem toy: Medical specialty drug. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- PAH background therapy: Sotatercept was studied and is used as an add-on to established PAH therapies; the combination and monitoring plan belongs to the treating specialist. trial
- Not a solo research run: Sotatercept is a serious prescription biologic used within a PAH treatment plan; background prostacyclin or antithrombotic therapy can also affect bleeding risk. trial
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Major labeled risks: WINREVAIR can cause erythrocytosis with thromboembolic or hyperviscosity risk, severe thrombocytopenia and serious bleeding; the label also warns of embryo-fetal toxicity and impaired fertility. Hemoglobin and platelet monitoring and specialist-directed dose holds or changes are part of treatment. trial
- Serious bleeding: Serious bleeding, including intracranial and gastrointestinal bleeding, has been reported. Risk was more likely with prostacyclin background therapy, antithrombotic agents or low platelet counts; do not administer during serious bleeding. trial
- Common adverse reactions: The current label lists headache, nosebleeds, rash, telangiectasia, diarrhea, dizziness, erythema, increased hemoglobin, gingival bleeding and infections among common reactions. trial
- Pregnancy and fertility: Animal data indicate embryo-fetal harm. The label calls for pregnancy testing and effective contraception during treatment and for four months after the last dose, and warns that fertility may be impaired. trial
- Postmarketing signal: Intrapulmonary right-to-left shunting has been reported after approval; voluntary reports cannot establish frequency or causality. trial
- Specialist treatment: Dose timing and adjustment depend on hemoglobin, platelet count and bleeding status. Sotatercept is not a gray-market research chemical or self-directed bodybuilding protocol. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.